Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
University of Colorado, Denver
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05089370CT.gov Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | — | Active Not Recruiting | — | — | — |
NCT02650986CT.gov Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | — | Active Not Recruiting | — | — | — |
NCT02839694CT.gov Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | — | Withdrawn | — | — | — |
NCT01876641CT.gov Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | — | Terminated | — | — | — |
NCT00791271CT.gov Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | University of Colorado, Denver | P1/2 | CCC · 52 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BBB · 72 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 70 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →